ArticleTranslational cancer research2026
Phase separation of MARCH1 promotes rectal adenocarcinoma progression through PHLPP2 ubiquitination.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Membrane-associated RING-CH 1 (MARCH1) is an E3 ubiquitin ligase that functions as an oncogene in colorectal cancer, but its role in rectal adenocarcinoma (READ) remains unclear. This study aimed to explore the effects of MARCH1 phase separation-mediated PHLPP2 ubiquitination on READ progression. Methods: MARCH1 expression was analyzed in normal and READ cell lines (SW480 and HT-29). The intrinsically disordered region (IDR) of MARCH1 was identified using Predictor of Natural Disordered Regions (PONDR), and an IDR point-mutant recombinant protein was generated. Lentiviruses were used to knock down MARCH1 or express IDR-mutant MARCH1 (MARCH1-MUT) in HT-29 cells. MG132 was used to inhibit the proteasome. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), Western blot, and immunoprecipitation were utilized to determine gene expression, protein, and ubiquitination levels. Cell proliferation and migration were assessed using cell counting kit-8 (CCK-8) and transwell assays. MARCH1 phase separation was evaluated using droplet formation, fluorescence recovery after photobleaching (FRAP), and immunofluorescence assays. Results: MARCH1 was highly expressed in READ cells. Conclusions: Phase separation of MARCH1 promotes the proteasomal degradation of PHLPP2 via ubiquitination, thereby facilitating READ progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.